MRC1 and endometrial cancer: In parallel, immune checkpoint inhibitors (ICIs), such as pembrolizumab and dostarlimab, have demonstrated significant clinical benefit in advanced and recurrent MMR-deficient endometrial cancer, while combination regimens involving ICIs and chemotherapy have expanded therapeutic options even for MMR-proficient tumors [6,7,8].